544 related articles for article (PubMed ID: 34097287)
1. Restoring Protein Expression in Neuromuscular Conditions: A Review Assessing the Current State of Exon Skipping/Inclusion and Gene Therapies for Duchenne Muscular Dystrophy and Spinal Muscular Atrophy.
Sheikh O; Yokota T
BioDrugs; 2021 Jul; 35(4):389-399. PubMed ID: 34097287
[TBL] [Abstract][Full Text] [Related]
2. Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy.
Iftikhar M; Frey J; Shohan MJ; Malek S; Mousa SA
Pharmacol Ther; 2021 Apr; 220():107719. PubMed ID: 33130193
[TBL] [Abstract][Full Text] [Related]
3. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
4. Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy.
Abreu NJ; Waldrop MA
Pediatr Pulmonol; 2021 Apr; 56(4):710-720. PubMed ID: 32886442
[TBL] [Abstract][Full Text] [Related]
5. New developments in exon skipping and splice modulation therapies for neuromuscular diseases.
Touznik A; Lee JJ; Yokota T
Expert Opin Biol Ther; 2014 Jun; 14(6):809-19. PubMed ID: 24620745
[TBL] [Abstract][Full Text] [Related]
6. Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy.
Dzierlega K; Yokota T
Gene Ther; 2020 Sep; 27(9):407-416. PubMed ID: 32483212
[TBL] [Abstract][Full Text] [Related]
7. Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.
Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():79-90. PubMed ID: 30171536
[TBL] [Abstract][Full Text] [Related]
8. Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle.
Vita G; Vita GL; Musumeci O; Rodolico C; Messina S
Neurol Sci; 2019 Apr; 40(4):671-681. PubMed ID: 30805745
[TBL] [Abstract][Full Text] [Related]
9. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
Maruyama R; Yokota T
Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
[TBL] [Abstract][Full Text] [Related]
10. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
[TBL] [Abstract][Full Text] [Related]
11. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Exon Skipping and Dystrophin Restoration in In Vitro Models of Duchenne Muscular Dystrophy.
López-Martínez A; Soblechero-Martín P; Arechavala-Gomeza V
Methods Mol Biol; 2022; 2434():217-233. PubMed ID: 35213020
[TBL] [Abstract][Full Text] [Related]
13. Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies.
Sheikh O; Yokota T
Expert Opin Investig Drugs; 2021 Feb; 30(2):167-176. PubMed ID: 33393390
[TBL] [Abstract][Full Text] [Related]
14. Recent advancements in exon-skipping therapies using antisense oligonucleotides and genome editing for the treatment of various muscular dystrophies.
Hwang J; Yokota T
Expert Rev Mol Med; 2019 Oct; 21():e5. PubMed ID: 31576784
[TBL] [Abstract][Full Text] [Related]
15. Golodirsen for Duchenne muscular dystrophy.
Anwar S; Yokota T
Drugs Today (Barc); 2020 Aug; 56(8):491-504. PubMed ID: 33025945
[TBL] [Abstract][Full Text] [Related]
16. Splicing therapy for neuromuscular disease.
Douglas AG; Wood MJ
Mol Cell Neurosci; 2013 Sep; 56():169-85. PubMed ID: 23631896
[TBL] [Abstract][Full Text] [Related]
17. Duchenne muscular dystrophy: Current treatment and emerging exon skipping and gene therapy approach.
Patterson G; Conner H; Groneman M; Blavo C; Parmar MS
Eur J Pharmacol; 2023 May; 947():175675. PubMed ID: 36963652
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
[TBL] [Abstract][Full Text] [Related]
19. Contributions of Japanese patients to development of antisense therapy for DMD.
Matsuo M; Takeshima Y; Nishio H
Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
[TBL] [Abstract][Full Text] [Related]
20. Viltolarsen: a treatment option for Duchenne muscular dystrophy patients who are amenable to exon 53 skipping therapy.
Czifrus E; Berlau DJ
Expert Rev Neurother; 2023; 23(10):853-858. PubMed ID: 37572081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]